Think of it this way lifestyle changes slow down the problem
Again, leveraging technology makes a big difference
Saxendas approval set a precedent in efficacy and pricing, with a cost of over $1,000 per month
Data on tirzepatide in fatty liver disease Within a substudy with 296 participants of the SURPASS-3 trial (SURPASS-3 MRI), changes in liver fat and other fat compartments were monitored during the study, and a subgroup of the tirzepatide cohort was compared to the insulin degludec comparator subgroup (54, 79)
In parallel, we are exploring molecular detection strategies to better capture low-level pathogen populations in complex matrices, as part of our broader effort to understand pathogen persistence and early contamination events, with implications for environmental monitoring strategies